2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2837

Sulfasalazine Comedication: A Predictor of Reduced Long-Term Anti-TNF Switch in Ankylosing Spondylitis
Abstract Number: 568

Superiority of Initial Combination- over Step up Therapy in Treatment to the Target of Remission in Daily Clinical Practice in Early Rheumatoid Arthritis Patients: Results from the DREAM Registry
Abstract Number: 1194

Support for Community-Based Programs for Managing Hip and Knee Osteoarthritis: Results of a Public Survey
Abstract Number: 1682

Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor
Abstract Number: 1138

Suppressor of Cytokine Signaling 1 Inhibits Interleukin-1β Induced Matrix Metalloproteinases Expression in Human Chondrocytes By Modulating p38-CREB- C/Ebpβ Pathway
Abstract Number: 114

Surfing the Net: Patient Empowerment or Patient Deceit? Fifteen-Year Trends on the World Wide Web Information for Patients with Rheumatoid Arthritis
Abstract Number: 1453

Surveillance of Periodic Fever Syndromes in Canada
Abstract Number: 2739

Survival of Etanercept (ETN) Responders after Methotrexate (MTX) Failure When ETN Is Initiated As Mono or Combination Therapy or after MTX Withdrawal from ETN/MTX Combination in Long Standing Rheumatoid Arthritis (RA). a Single Center Retrospective Study
Abstract Number: 2588

Survivin Links Smoking and High Prevalence of Rheumatoid Arthritis in Women
Abstract Number: 2506

Sustained Improvement in Teratogenic Risk Education in a Pediatric Rheumatology Clinic
Abstract Number: 3265

Sustaining Employment with Arthritis: Can Existing Workplace Policies and Accommodations Make a Difference?
Abstract Number: 1664

Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.
Abstract Number: 1872

Symptomatic and Electrodiagnostic Features of Peripheral Neuropathy in Scleroderma
Abstract Number: 197

Synergy Between Hematopoietic and Radioresistant Stromal Cells Is Required for Autoimmune Manifestations of Dnase II Deficient Mice
Abstract Number: 2446

Synovial Fluid Proteins Differentiate Patients with Oligoarticular Juvenile Idiopathic Arthritis Who Are Destined to Extend from Those Who Will Remain Persistent in Course

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].